CVRx Inc. launches a European registry to track treatment with its Barostim neo heart implant for patients with drug-resistant hypertension.
MASSDEVICE ON CALL — Minneapolis-based CVRx Inc. launched a European registry to track treatment with its Barostim neo device, a heart implant for treatment of drug-resistant hypertension.
The Barostim neo device is designed to trigger the body's natural blood flow regulation system by activating the baroreceptors, located in the carotid artery, which regulate cardiovascular function.
The stimulation effectively tells the arteries to relax, the heart to slow down and the kidneys to reduce fluid in the body, resulting in reduced cardiac exertion, reducing the workload on the heart, according to a press release.
The new registry is expected to enroll up to 500 patients and track performance outcomes and physician experience.
MicroVention launches study of coiling technologies for brain aneurysms
Tustin, Calif.-based MicroVention began enrollment in a clinical trial comparing coiling technologies used to treat intracranial aneurysms.
The prospective, randomized, international multicenter trial will enroll up to 600 subjects in a study pitting new generation MicroVention hydrogen coils against bare platinum coils.
Patients who've already had coronary artery bypass graft surgery showed a significant mortality...
Johnson & Johnson has no proof that any of the thousands of pelvic mesh lawsuits filed against it...
USGI Medical says it raised $19.5 million in new debt and equity financing to fuel international...
The FDA's Center for Devices & Radiological Health reports significant progress in expediting...
BioStructures wins the FDA's blessing for a next-generation bone graft product.